When do the patents on MARCAINE HYDROCHLORIDE expire, and when will generic MARCAINE HYDROCHLORIDE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	MARCAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;INJECTION	016964-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-008	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	MARCAINE HYDROCHLORIDE PRESERVATIVE FREE	bupivacaine hydrochloride	INJECTABLE;INJECTION	016964-005	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 17, 2026

Marcaine Hydrochloride (bupivacaine HCl) investment scenario and patent/IP fundamentals

Marcaine Hydrochloride is an off-patent local anesthetic (bupivacaine HCl) with broad generic availability in the US. The investment case is therefore driven by (1) formulary access and price erosion dynamics, (2) ongoing demand for specific dosage forms (injection) and concentrations, (3) risk-adjusted execution in FDA CMC and labeling, and (4) any remaining, narrower IP such as controlled-release or method-of-use coverages by specific branded sponsors in targeted markets. From an IP standpoint, the brand’s value proposition has shifted from exclusivity to brand-specific differentiation and contract pricing.

What patents protect Marcaine Hydrochloride (bupivacaine HCl) and who owns them?

Direct answer: For US commercial use, Marcaine Hydrochloride is built on bupivacaine HCl, which is widely generic. Patent protection, where it exists today, is typically not on the base API but on specific branded presentations, manufacturing processes, packaging, or narrower methods of use.

How to think about the bupivacaine patent landscape

Key IP layers that can still matter economically for an investor or licensee:

API composition patents: usually expired for first-wave bupivacaine brands.
Formulation and concentration-specific patents: can persist longer if a branded product had unique excipient systems, pH control, or stabilizers.
Method-of-use patents: block generic substitution only if the Orange Book lists method-of-use and the ANDA is carved out or fails to do so.
Process patents (manufacturing): can affect CMC equivalence but typically do not stop ANDAs unless tightly connected to product characteristics in Orange Book listings.
Device/administration IP: less common for plain injection but relevant for needle kits or specific delivery systems, if any.

Brand vs. generic reality

Even when a brand lists patents historically, today’s market behavior for bupivacaine HCl injections usually reflects:

rapid generic entry,
heavy payer substitution,
price compression.

That means an investor’s “patent thesis” must be product-specific (which concentration, which label indications, which dosing form) rather than API-generic.

When does Marcaine Hydrochloride lose exclusivity (US) and what does that imply for pricing?

Direct answer: Marcaine Hydrochloride’s practical exclusivity in the US is largely past its peak. Generics have been available for years, producing structural price erosion. Any remaining exclusivity is typically narrow and tied to specific branded presentations or label carve-outs.

Implications for investment underwriting

Gross margin profile: typically low versus on-patent products unless the buyer holds a differentiated distribution contract, a niche hospital formulary position, or a protected presentation.
Demand elasticity: high because bupivacaine HCl is substitutable within local anesthetic classes and commonly viewed as interchangeable by formularies.
Channel dynamics: wholesalers and group purchasing organizations drive net price more than brand loyalty.

Timing risk

For a new entrant (generic or 505(b)(2)):

If there is no Orange Book-relevant exclusivity, market timing risk shifts from “patent blocking” to “CMC and bioequivalence acceptance” risk.
If there are listed patents, the economic question becomes: can you design around them and still be allowed to market promptly?

What is the Orange Book status of Marcaine Hydrochloride (bupivacaine HCl) and how does it affect generic entry risks?

Direct answer: The Orange Book status for bupivacaine HCl injections generally shows broad patent listings historically but today the commercial footprint is predominantly generic. For investment, the operative factor is whether any currently listed patents cover the specific NDC strength/presentation that the investor targets.

Featured snippet style take

If the Orange Book for the exact NDC lists no unexpired patents or if the ANDA can be carved out, generic entry risk is CMC and regulatory driven.
If the Orange Book lists unexpired patents with method-of-use coverage, generic entry can require Paragraph IV challenges, settlements, or licensing.

Practical underwriting

Market entry math: entry timing plus expected payer discounts and hospital contracting dictates ROI more than patent count.
Litigation probability: for off-patent, the frequency of Paragraph IV disputes is lower; the remaining disputes are usually about specific presentations or new 505(b)(2) label expansions.

What patent litigation affects bupivacaine HCl injections, including Paragraph IV challenges and settlements?

Direct answer: For bupivacaine HCl, litigation is not the dominant feature of the current market because most core API protections have expired. Remaining disputes, when they occur, are typically presentation-specific or focus on whether a generic design avoids a listed method-of-use or formulation patent.

Where litigation still shows up

Method-of-use listings: can lead to Paragraph IV challenges if the ANDA certifies “not infringed” or “invalid.”
Formulation/process patents: can become relevant if the ANDA is alleged not to be equivalent in clinically meaningful characteristics.

Investment impact

License vs. litigate: most generics and 505(b)(2) entrants rationally prefer settlement if the only viable path is carve-out or design-around.
Damages and launch delay: a settlement can be economically meaningful if it includes forfeited exclusivity or delayed launch triggers.

What formulations are protected for Marcaine Hydrochloride and which delivery forms matter commercially?

Direct answer: For investment, formulations and concentrations are the main differentiators. If a brand or 505(b)(2) product used a unique excipient or specific concentration with label impact, that narrower IP could be the only remaining barrier.

Commercially relevant product attributes

Concentration (strength-specific NDCs): determines substitution behavior in hospital procurement.
Packaging: single-dose vs multi-dose impacts handling and cost.
Label indications: obstetrics, surgery anesthesia, nerve blocks, and epidural use can drive tender wins even within the same API.

Investor lens

A product that can only win by price will face rapid erosion. A product that can win by label specificity, stability/handling, or administration convenience may sustain pricing longer even with multiple generics.

How does Marcaine Hydrochloride compare with other local anesthetics on patent strength and competitive pressure?

Direct answer: Bupivacaine HCl faces high generic competitive pressure compared with branded depot or long-acting local anesthetics that retain meaningful IP (for example, certain extended-release formulations). Generic compression for simple solutions is structurally faster.

Relative competitiveness

Simple bupivacaine solution (Marcaine HCl): typically high competition, low patent leverage.
Long-acting / depot systems: often more IP and fewer direct substitutes.
Other local anesthetic classes (lidocaine, mepivacaine, ropivacaine): competition exists but the switch is driven by safety perception, duration, and payer preference.

Investment implication

If the goal is to fund growth, the bupivacaine HCl line is usually not the core “IP engine.” It is the value-preservation platform unless the investor has a differentiated distribution or a specific form-factor advantage.

What generic entry risks exist for bupivacaine HCl injection and how do they show up in ROI?

Direct answer: For a generic or authorized generic entrant, “entry risk” is usually regulatory/CMC rather than patent. The ROI risk is pricing collapse and tender competitiveness.

Key ROI drivers

Net price trajectory after first and second wave generic entry.
Contracts: group purchasing and hospital system tenders can lock in low margin but stable volume.
Inventory and supply: local anesthetic demand is operating room and pain management cadence; supply shocks can temporarily lift prices.

Key cost and execution risks

CMC equivalence to reference listed conditions.
Labeling alignment: indications and warnings must match what the market needs.
Stability and shelf-life: affects cold chain or storage compliance and bid competitiveness.

Is there a biosimilar risk for Marcaine Hydrochloride?

Direct answer: No. Marcaine Hydrochloride is a small-molecule drug (bupivacaine HCl), not a biologic, so biosimilar frameworks and exclusivity do not apply.

What FDA status and regulatory pathway issues matter most for bupivacaine HCl injection?

Direct answer: Generic entry typically uses ANDA (or 505(b)(2) for certain label or formulation enhancements). The investment-relevant issues are bioequivalence, local tolerability in labeling, and CMC demonstration of sameness.

Regulatory considerations that affect launch economics

BE requirements: governs study timeline and cost.
Stability data: affects time to market and bid acceptance.
Label changes: if pursuing 505(b)(2) differentiation, label negotiation drives timelines more than chemistry does.

Which companies compete for bupivacaine HCl injection and what is the likely competitive structure?

Direct answer: The competitive structure in bupivacaine HCl injections is characterized by multiple authorized generics and independent generics, often with strong distributor and wholesaler relationships and frequent tender rotations.

Investment-relevant competitive patterns

Authorized generics: can compress prices quickly after originator or authorized sponsor changes.
Hospital formulary cycles: can shift utilization with limited clinical differentiation.
Availability and supply reliability: becomes a quasi-product differentiator when shortages occur.

What licensing or contract deal structures are typical for off-patent bupivacaine HCl products?

Direct answer: For off-patent small molecules, licensing is often supply-based (manufacturing and distribution rights) or tied to specific NDCs, rather than broad long-term exclusionary licensing.

Common deal economics

Low upfront, profit-share or margin share tied to volume and net price.
Termination and supply contingencies based on batch release, stability, and service levels.
Distribution exclusivity at the wholesaler or GPO contract level rather than legal exclusivity.

What is the revenue exposure profile for Marcaine Hydrochloride and how should investors model demand?

Direct answer: Revenue exposure is driven by procedural volume (surgery and anesthesia scheduling), pain management practices, and tender pricing. Long-run growth is typically modest versus volume growth or utilization shifts.

Modeling approach

Baseline demand: link to surgery volumes and regional utilization.
Price: use net price decline curves reflecting generic replacement waves.
Share: hospital system formularies and brand preference if any.

What moves the P&L

Contract wins/losses and rebate changes.
Supply constraints that affect allocation and short-term pricing.
Competitor tender pricing that dictates next-cycle discount levels.

How strong is the patent estate for bupivacaine HCl injections as an investment moat?

Direct answer: The patent estate for the base bupivacaine HCl product is not usually a durable moat. Any remaining protection is likely presentation- and label-specific. The moat in practice is execution and distribution.

Moat scoreboard

Patent leverage: low for core API injection.
Regulatory leverage: moderate (if differentiation is possible via label/formulation).
Execution moat: high for manufacturing reliability, supply chain, and bid competitiveness.
Commercial moat: tied to contracts and availability.

Key Takeaways

Marcaine Hydrochloride (bupivacaine HCl injection) is a small-molecule product with broad generic substitutability; patent-driven exclusivity is not the main value driver.
Investment upside typically depends on product presentation selection, contracting strategy, supply reliability, and CMC/regulatory execution rather than litigation outcomes.
The operational risk shifts from patent blocking to pricing erosion, tender dynamics, and launch timing relative to competitor waves.
Because it is not a biologic, biosimilar risk is not applicable; investor focus stays on ANDA/505(b)(2) regulatory pathways and product-specific Orange Book listings.

FAQs

1) What NDC-specific factors matter most for patent or exclusivity risk in bupivacaine HCl injections?
The exact strength, dosage form, and labeled indication set tied to the NDC and how Orange Book patents are listed against that product.

2) How should an investor assess whether to enter bupivacaine HCl via ANDA vs 505(b)(2)?
Use product differentiation feasibility: if the plan is label or formulation differentiation that meaningfully changes regulatory obligations, 505(b)(2) can be justified; otherwise ANDA supports faster, lower-cost entry.

3) What cost structure most affects profitability for generic bupivacaine HCl injection?
Manufacturing COGS, stability-linked shelf-life assumptions, batch release timing, and rebate/contract pass-through.

4) Do method-of-use patents meaningfully delay generic launches for local anesthetic injections?
They can if Orange Book method-of-use patents are unexpired and the ANDA certifications trigger litigation or carve-out requirements. For many bupivacaine presentations, this effect is usually limited due to widespread genericization.

5) What commercial indicators best predict net price outcomes for off-patent injectables like Marcaine HCl?
GPO contract history, tender pricing cycles, authorized generic competition timing, and local hospital rebate structures.

References (APA)

No sources were cited in the absence of provided Orange Book, FDA, or litigation identifiers for the specific Marcaine Hydrochloride product presentation.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for MARCAINE HYDROCHLORIDE